00:34 , Apr 4, 2014 |  BC Extra  |  Top Story

Corium raises $52 million in IPO

Drug delivery company Corium International Inc. (NASDAQ:CORI) raised $52 million through the sale of a bumped up number of shares below its proposed price range in an IPO on NASDAQ. The company sold 6.5 million...
00:17 , Mar 25, 2014 |  BC Extra  |  Financial News

Corium sets IPO range

Drug delivery company Corium International Inc. (Menlo Park, Calif.) amended its IPO on NASDAQ and now plans to sell 5.5 million shares at $10-$12. At the $11 midpoint, the company would raise $60.5 million and...
00:51 , Mar 6, 2014 |  BC Extra  |  Financial News

Drug delivery play Corium files for IPO

Corium International Inc. (Menlo Park, Calif.) filed to raise up to $50 million in an IPO on NASDAQ underwritten by Jefferies; Leerink; Needham; and FBR. Corium developed two transdermal drug delivery technologies: MicroCor, a biodegradable...
07:00 , Sep 2, 2013 |  BioCentury  |  Strategy

Back to School: Facing Reality

BC Staff  For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA, EMAand Japan's Pharmaceuticals and Medical Devices Agency are...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

TheraTech, P&G sales and marketing update

P&G began selling THRT's Alora estrogen replacement therapy patch. The patch, which is indicated to treat moderate-to-severe vasomotor menopausal symptoms, is available in three dosage strengths - 0.05, 0.075 and 0.1 mgs. Price wasn't...
08:00 , Dec 17, 2012 |  BioCentury  |  Strategy

Teva's puzzle pieces

Teva Pharmaceutical Industries Ltd.'s new management expects to achieve organic, profitable growth by globalizing key operating functions to reshape its cost structure while regionally tailoring its product offerings and using business development to amass capabilities...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Somaxon, Mylan, Zydus deal

Somaxon granted Mylan exclusive rights to sell an authorized generic version of insomnia drug Silenor doxepin in the U.S. for 180 days beginning January 2020. Under undisclosed circumstances, Mylan's right to sell the authorized...
07:00 , May 14, 2012 |  BioCentury  |  Strategy

Outcomes trumping volume

In their quest to establish value for money, payers in the U.S. are asking drug manufacturers to experiment with new contracting models that tie rebates and discounts to health outcomes instead of drug volumes. At least...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Company News

Somaxon, P&G deal

Somaxon said Procter & Gamble declined to exercise its option to negotiate for OTC rights to Somaxon's insomnia drug Silenor doxepin. P&G, which no longer has any rights to the product, gained the right...
08:00 , Jan 16, 2012 |  BioCentury  |  Strategy

Rebooting confidence

When Jeremy Levin takes the helm as president and CEO of Teva Pharmaceutical Industries Ltd. in May, he will be taking on the huge task of restoring investor confidence in the company and its growth...